Oceania: Food, Drugs, Healthcare, Life Sciences

Artificial intelligence (AI) is revolutionising healthcare, offering transformative potential in diagnostics, treatment planning, and patient care. However, its rapid integration into health practice presents significant legal, regulatory, and ethical challenges. This article explores emerging technologies and provides insights into the current regulatory landscape and key risk areas associated with AI in healthcare.

Health and life sciences continue to rapidly emerge as a major sector in Australia’s economy, driving innovation, medical advancement and scientific understanding. As the sector grows, however, it is increasingly exposed to scrutiny around integrity and the consequences that follow when confidence in research and quality is questioned.

Australia’s health and life sciences sector is growing rapidly, and with that growth comes a more complex web of legal exposure for the organisations that operate within it. The recent Bartier Perry panel event, Health and Life Sciences: Research Integrity Under the Microscope, explored how failures in data and research integrity translate into real-world risk.

A prisoner made an application to Queensland Corrective Services seeking to have some of her eggs extracted and frozen so that she may undergo ‘assisted reproductive technology’ upon her release from imprisonment.

A case on appeal in NSW focused on whether a sentence handed down for drug supply charges was excessive.

Synergistic combinations in patent law present unique challenges for inventors in chemical, pharmaceutical, and life sciences fields. While combining known components is common practice, only those combinations producing effects greater than the sum of their parts can constitute patentable inventions. This article explores the legal requirements, evidentiary standards, and practical strategies for successfully claiming synergistic effects under Australian patent law.

Artificial intelligence (AI) is revolutionising healthcare, offering transformative potential in diagnostics, treatment planning, and patient care. However, its rapid integration into health practice presents significant legal, regulatory, and ethical challenges. This article explores emerging technologies and provides insights into the current regulatory landscape and key risk areas associated with AI in healthcare.

New South Wales has become the first Australian state to introduce a conditional registration scheme for medicinal cannabis patients, replacing automatic drug driving penalties with a threshold-based system. The reform requires patients to register with Transport for NSW and complete mandatory education, but questions remain about whether the new framework adequately balances road safety with patient rights.

A Victorian tribunal found a coordinating doctor guilty of professional misconduct after an administrative error in the voluntary assisted dying process led to a patient signing their written declaration without required witnesses present. The case examines the heightened responsibility practitioners face when managing VAD documentation and the disciplinary consequences of failing to ensure strict compliance with procedural safeguards, even when errors are unintentional.